Anti-VEGF Agents Tied to Improved Visual Acuity in Diabetic Macular Edema (FREE)
By Kelly Young
Edited by Susan Sadoughi, MD
Aflibercept (Eylea), bevacizumab (Avastin), and ranibizumab (Lucentis) all lead to improved vision in patients with diabetic macular edema, although aflibercept may be most effective for those with the worst baseline vision, a New England … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 19, 2015 Category: Primary Care Source Type: news
3 Drugs for an Eye Disease, With Big Price Gaps, Are Found to Be Equals for Many
The three drugs — Eylea, Lucentis and Avastin — are meant to treat a condition known as macular edema, which occurs primarily in patients with diabetes. (Source: NYT Health)
Source: NYT Health - February 18, 2015 Category: Consumer Health News Authors: By ANDREW POLLACK Tags: Eyes and Eyesight Roche Holding AG RHHBY Other OTC National Eye Institute Research Eylea (Drug) Regeneron Pharmaceuticals Inc REGN NASDAQ Source Type: news
Study Compares Drugs for Diabetes-Linked Eye Disease
Eylea has slight advantage over Avastin, Lucentis for people with macular edema, but cost is an issue
Source: HealthDay
Related MedlinePlus Pages: Diabetic Eye Problems, Eye Diseases, Retinal Disorders (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 18, 2015 Category: Consumer Health News Source Type: news
Ranibizumab reverses vision loss caused by diabetes
(University of Southern California - Health Sciences) Ranibizumab, a prescription drug commonly used to treat age-related vision loss, also reverses vision loss caused by diabetes among Hispanic and non-Hispanic whites, according to a new study led by investigators from the University of Southern California Eye Institute. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 18, 2015 Category: Global & Universal Source Type: news
Eylea outperforms other drugs for diabetic macular edema with moderate or worse vision loss
In an NIH-supported clinical trial comparing three drugs for diabetic macular edema (DME), Eylea (aflibercept) provided greater visual improvement, on average, than did Avastin (bevacizumab) or Lucentis (ranibizumab) when vision was 20/50 or worse at the start of the trial. However, the three drugs resulted in similar average improvement when starting vision was 20/40 to 20/32. Investigators found no major differences in the safety of the three drugs. The trial was funded by the National Eye Institute (NEI), part of the National Institutes of Health.
Language
English (Source: News from NEI)
Source: News from NEI - February 16, 2015 Category: Opthalmology Authors: Jason Source Type: news
BRVO: Bevacizumab and Ranibizumab Both EffectiveBRVO: Bevacizumab and Ranibizumab Both Effective
Treatment with anti-VEGF therapy results in rapid improvements in anatomy and function in patients with macular edema caused by branch retinal vein occlusion. Medscape Medical News (Source: Medscape Ophthalmology Headlines)
Source: Medscape Ophthalmology Headlines - February 11, 2015 Category: Opthalmology Tags: Ophthalmology News Source Type: news
Pfenex and Hospira to develop Lucentis biosimilar candidate
Clinical-stage biotechnology firm Pfenex has partnered with Hospira to develop and commercialise PF582, Pfenex's biosimilar candidate to Genentech's Lucentis (ranibizumab injection). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 11, 2015 Category: Pharmaceuticals Source Type: news
Lucentis Approved for Diabetic Retinopathy
Title: Lucentis Approved for Diabetic RetinopathyCategory: Health NewsCreated: 2/9/2015 12:00:00 AMLast Editorial Review: 2/10/2015 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - February 10, 2015 Category: Endocrinology Source Type: news
Lucentis Approved for Diabetic Retinopathy
Among diabetics with macular edemaSource: HealthDay
Related MedlinePlus Pages: Diabetic Eye Problems, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - February 9, 2015 Category: Consumer Health News Source Type: news
FDA approves Roche's Lucentis (ranibizumab injection) for treatment of diabetic retinopathy in people with diabetic macular edema
Roche announced today that the U.S. Food and Drug Administration (FDA) approved Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy (DR), in people with diabetic macular edema (DME). DME impacts nearly 750,000 Americans, about 10 percent of people with DR. (Source: Roche Investor Update)
Source: Roche Investor Update - February 9, 2015 Category: Pharmaceuticals Source Type: news
FDA approves Roche's Lucentis (ranibizumab injection) for treatment of diabetic retinopathy in people with diabetic macular edema
Roche announced today that the U.S. Food and Drug Administration (FDA) approved Lucentis (ranibizumab injection) for the treatment of diabetic retinopathy (DR), in people with diabetic macular edema (DME). DME impacts nearly 750,000 Americans, about 10 percent of people with DR. (Source: Roche Media News)
Source: Roche Media News - February 9, 2015 Category: Pharmaceuticals Source Type: news
Ranibizumab Approved to Treat Diabetic Retinopathy (FREE)
By The Editors
The FDA has approved ranibizumab (Lucentis) to treat diabetic retinopathy in patients who have diabetic macular edema.Ranibizumab, previously … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 9, 2015 Category: Primary Care Source Type: news
FDA Clears Ranibizumab for Diabetic Retinopathy With DMEFDA Clears Ranibizumab for Diabetic Retinopathy With DME
Ranibizumab for diabetic retinopathy with DME had breakthrough therapy designation and was reviewed under the agency's priority review program. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 6, 2015 Category: Consumer Health News Tags: Ophthalmology News Alert Source Type: news
FDA approves Lucentis to treat diabetic retinopathy in patients with diabetic macular edema
The U.S. Food and Drug Administration today expanded the approved use for Lucentis (ranibizumab injection) 0.3 mg to treat diabetic retinopathy (DR) in patients with diabetic macular edema (DME). (Source: Food and Drug Administration)
Source: Food and Drug Administration - February 6, 2015 Category: American Health Source Type: news
